CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: QPCTL (ImmuneEditome ID:54814)

1. Gene summary of enriched editing regions for QPCTL

check button Gene summary
Gene informationGene symbol

QPCTL

Gene ID

54814

GeneSynonymsgQC
GeneCytomap

19q13.32

GeneTypeprotein-coding
GeneDescriptionglutaminyl-peptide cyclotransferase-like protein|glutaminyl cyclase-like|golgi-resident glutaminyl-peptide cyclotransferase|isoQC
GeneModificationdate20230517
UniprotIDQ9NXS2;A0A7I2V353;A0A7I2V5X1;K7EQG1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:45693882-45696559:+ENST00000012049.8ENSG00000011478.10QPCTLexonicAluSp,AluSx1,L2c,MIR,AluSx3,FLAM_C,AluSg7,L2achr19:45693882-45696559:+.alignment
chr19:45693882-45696559:+ENST00000591606.1ENSG00000011478.10QPCTLexonicAluSp,AluSx1,L2c,MIR,AluSx3,FLAM_C,AluSg7,L2achr19:45693882-45696559:+.alignment
chr19:45699762-45700284:+ENST00000592769.1ENSG00000011478.10QPCTLncRNA_intronicAluJb,AluSx,AluSx4chr19:45699762-45700284:+.alignment
chr19:45703307-45703982:+ENST00000012049.8ENSG00000011478.10QPCTLUTR3AluSx1,AluYchr19:45703307-45703982:+.alignment
chr19:45703307-45703982:+ENST00000366382.7ENSG00000011478.10QPCTLUTR3AluSx1,AluYchr19:45703307-45703982:+.alignment


Top

2. Tumor-specific enriched editing regions for QPCTL


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:45703307-45703982:+BRCAEER2.2732e-02image
ENSG00000011478.10,QPCTLBRCAEAG2.2252e-02image
chr19:45703307-45703982:+KIRCEER4.0582e-02image
ENSG00000011478.10,QPCTLKIRCEAG3.6343e-02image
chr19:45703307-45703982:+LIHCEER6.2972e-03image
ENSG00000011478.10,QPCTLLIHCEAG6.2985e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:45703307-45703982:+UCECCliEER1.8328e-021.2055e-02-0.1100image
ENSG00000011478.10,QPCTLUCECCliEAG1.8309e-021.2041e-02-0.1100image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:45703307-45703982:+COADEER5.6080e-031.4083e-028.9451e+00image
ENSG00000011478.10,QPCTLCOADEAG5.6080e-031.2761e-029.1796e+00image
ENSG00000011478.10,QPCTLESCAEAG1.4991e-023.9782e-021.6228e-02image

Top

3. Enriched editing regions and immune related genes for QPCTL


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:45703307-45703982:+LIHCEERENSG00000100138,NHP2L1-0.38658.0936e-101.6085e-14-0.4111imageNNNAMacrophages_M0GSVA_HALLMARK_MYC_TARGETS_V2
chr19:45703307-45703982:+GBMEERENSG00000133195,SLC39A110.39312.1640e-041.3290e-070.4072imageNNNAMast_cells_restingGSVA_HALLMARK_DNA_REPAIR
chr19:45703307-45703982:+GBMEERENSG00000198868,CTB-36O1.40.29601.0841e-021.3789e-080.4351imageNNNAMonocytesGSVA_HALLMARK_MYC_TARGETS_V1
chr19:45703307-45703982:+KIRCEERENSG00000100580,TMED80.39145.3077e-104.2452e-140.4127imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+KIRCEERENSG00000118922,KLF120.37872.9381e-096.5614e-140.4099imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+KIRCEERENSG00000136874,STX170.37723.0843e-095.6410e-140.4109imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45703307-45703982:+KIRCEERENSG00000186063,AIDA0.38215.1143e-092.5900e-130.4008imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+KIRCEERENSG00000033800,PIAS10.37415.7601e-091.7852e-140.4183imageNNPIAS1T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+KIRCEERENSG00000107290,SETX0.37138.7877e-097.2246e-140.4093imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45703307-45703982:+KIRCEERENSG00000096717,SIRT10.36441.8816e-085.3858e-140.4112imageNNSIRT1T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+LIHCEERENSG00000100138,NHP2L1-0.38658.0936e-101.6085e-14-0.4111imageNNNAMacrophages_M0GSVA_HALLMARK_MYC_TARGETS_V2
chr19:45703307-45703982:+GBMEERENSG00000133195,SLC39A110.39312.1640e-041.3290e-070.4072imageNNNAMast_cells_restingGSVA_HALLMARK_DNA_REPAIR
chr19:45703307-45703982:+GBMEERENSG00000198868,CTB-36O1.40.29601.0841e-021.3789e-080.4351imageNNNAMonocytesGSVA_HALLMARK_MYC_TARGETS_V1
chr19:45703307-45703982:+KIRCEERENSG00000100580,TMED80.39145.3077e-104.2452e-140.4127imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+KIRCEERENSG00000118922,KLF120.37872.9381e-096.5614e-140.4099imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+KIRCEERENSG00000136874,STX170.37723.0843e-095.6410e-140.4109imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45703307-45703982:+KIRCEERENSG00000186063,AIDA0.38215.1143e-092.5900e-130.4008imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+KIRCEERENSG00000033800,PIAS10.37415.7601e-091.7852e-140.4183imageNNPIAS1T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr19:45703307-45703982:+KIRCEERENSG00000107290,SETX0.37138.7877e-097.2246e-140.4093imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:45703307-45703982:+KIRCEERENSG00000096717,SIRT10.36441.8816e-085.3858e-140.4112imageNNSIRT1T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

4. Enriched editing regions and immune related splicing for QPCTL


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000011478.10,QPCTL
TGCTEAGA5ENSG00000116922.10chr137689657:37689883:37690333:37690438:37690215:376904380.32372.3783e-032.9955e-050.4083imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAGSVA_HALLMARK_DNA_REPAIR
chr19:45703307-45703982:+
TGCTEERA5ENSG00000116922.10chr137689657:37689883:37690333:37690438:37690215:376904380.33221.9370e-031.8771e-050.4177imageNNNAGSVA_HALLMARK_DNA_REPAIR
ENSG00000011478.10,QPCTL
THYMEAGMEXENSG00000142330.15chr2240595233:240595304:240595933:240596152:240596849:240596942:240597887:2405980870.49941.4556e-036.6936e-050.4119imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184CAPN10T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000011478.10,QPCTL
THYMEAGIRENSG00000076513.12chr12110027213:110027766:110028511:110028642-0.44014.2782e-031.2219e-04-0.4025imageNADAR;AIFM1;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAMacrophages_M1GSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+
THYMEERMEXENSG00000171298.8chr1780111982:80112100:80112577:80112711:80113217:80113366:80116967:801170820.46044.5741e-031.0804e-050.4525imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+
THYMEERMEXENSG00000115486.7chr285554142:85554306:85555483:85555590:85560814:85560985:85561385:855614730.41918.9167e-031.0487e-050.4580imageNNGGCXT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+
THYMEERMEXENSG00000169919.12chr765974525:65974704:65974918:65976202:65979833:65979911:65980223:65980409-0.40791.1393e-022.0579e-05-0.4491imageNNGUSBT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+
THYMEERIRENSG00000145604.11chr536177138:36177292:36183839:361840290.39351.6837e-023.2426e-050.4322imageNNSKP2T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000011478.10,QPCTL
THYMEAGMEXENSG00000244754.4chr1332521372:32521449:32522181:32523082:32527457:32527532:32535768:32535869-0.54361.2628e-041.0938e-06-0.4950imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr19:45703307-45703982:+
THYMEERMEXENSG00000115204.10chr227309903:27309981:27311898:27312246:27312547:27312589:27312679:27312772-0.51606.3617e-043.4024e-06-0.4722imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for QPCTL


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:45703307-45703982:+ACCEERMacrophages_M22.6767e-020.2667image
ENSG00000011478.10,QPCTLACCEAGMacrophages_M22.6626e-020.2669image
chr19:45703307-45703982:+BLCAEERMacrophages_M18.0602e-080.2738image
ENSG00000011478.10,QPCTLBLCAEAGMacrophages_M16.6607e-080.2751image
chr19:45703307-45703982:+BRCAEERNeutrophils8.9155e-040.1068image
ENSG00000011478.10,QPCTLBRCAEAGNeutrophils4.9048e-040.1118image
chr19:45703307-45703982:+CESCEERMacrophages_M11.2839e-030.2013image
ENSG00000011478.10,QPCTLCESCEAGMacrophages_M11.2909e-030.2012image
chr19:45703307-45703982:+CHOLEERNK_cells_activated1.3042e-030.6066image
ENSG00000011478.10,QPCTLCHOLEAGNK_cells_activated1.3032e-030.6067image
chr19:45703307-45703982:+COADEERMacrophages_M24.7007e-020.1294image
ENSG00000011478.10,QPCTLCOADEAGMacrophages_M22.2811e-020.1475image
chr19:45703307-45703982:+DLBCEEREosinophils6.0817e-030.3904image
ENSG00000011478.10,QPCTLDLBCEAGEosinophils6.0419e-030.3907image
ENSG00000011478.10,QPCTLESCAEAGNK_cells_resting2.3593e-03-0.3764image
chr19:45703307-45703982:+HNSCEERMacrophages_M15.6215e-060.2420image
ENSG00000011478.10,QPCTLHNSCEAGMacrophages_M15.6215e-060.2420image
chr19:45703307-45703982:+KICHEERT_cells_CD4_memory_resting4.9845e-020.3010image
ENSG00000011478.10,QPCTLKICHEAGT_cells_CD4_memory_resting4.9845e-020.3010image
chr19:45703307-45703982:+KIRCEERT_cells_regulatory_(Tregs)8.0661e-04-0.1899image
ENSG00000011478.10,QPCTLKIRCEAGT_cells_regulatory_(Tregs)1.2844e-03-0.1824image
chr19:45703307-45703982:+KIRPEERT_cells_regulatory_(Tregs)7.7933e-03-0.1669image
ENSG00000011478.10,QPCTLKIRPEAGT_cells_regulatory_(Tregs)7.6336e-03-0.1674image
chr19:45703307-45703982:+LGGEERMacrophages_M11.4640e-02-0.1728image
ENSG00000011478.10,QPCTLLGGEAGMacrophages_M11.4640e-02-0.1728image
chr19:45703307-45703982:+LIHCEERMacrophages_M01.1408e-04-0.2137image
ENSG00000011478.10,QPCTLLIHCEAGMacrophages_M01.1426e-04-0.2137image
chr19:45703307-45703982:+LUSCEERMacrophages_M22.1527e-020.1098image
ENSG00000011478.10,QPCTLLUSCEAGMacrophages_M22.6569e-020.1060image
chr19:45703307-45703982:+MESOEERMonocytes3.1718e-020.2800image
ENSG00000011478.10,QPCTLMESOEAGMonocytes3.1718e-020.2800image
chr19:45693882-45696559:+OVEERMonocytes1.4424e-030.4345image
chr19:45703307-45703982:+OVEERNeutrophils1.9784e-020.1516image
ENSG00000011478.10,QPCTLOVEAGMacrophages_M14.0202e-02-0.1320image
chr19:45703307-45703982:+PAADEERMacrophages_M01.8664e-02-0.1912image
ENSG00000011478.10,QPCTLPAADEAGMacrophages_M01.9246e-02-0.1903image
chr19:45703307-45703982:+PCPGEERMacrophages_M12.7344e-030.2414image
ENSG00000011478.10,QPCTLPCPGEAGMacrophages_M12.6936e-030.2418image
chr19:45703307-45703982:+PRADEERT_cells_CD4_memory_resting4.3913e-020.0909image
ENSG00000011478.10,QPCTLPRADEAGT_cells_CD4_memory_resting2.5209e-020.1008image
chr19:45703307-45703982:+READEERMonocytes4.4786e-030.3127image
ENSG00000011478.10,QPCTLREADEAGMonocytes4.5877e-030.3119image
chr19:45703307-45703982:+SARCEERMast_cells_resting5.9583e-060.3348image
ENSG00000011478.10,QPCTLSARCEAGMast_cells_resting5.9583e-060.3348image
chr19:45693882-45696559:+SKCMEERNeutrophils4.1411e-020.4193image
chr19:45703307-45703982:+SKCMEERT_cells_CD81.0534e-060.2253image
ENSG00000011478.10,QPCTLSKCMEAGT_cells_CD89.5763e-070.2261image
chr19:45703307-45703982:+STADEERT_cells_regulatory_(Tregs)1.2161e-020.2499image
ENSG00000011478.10,QPCTLSTADEAGMacrophages_M24.7758e-030.2398image
chr19:45703307-45703982:+THCAEERT_cells_CD81.2727e-04-0.1755image
ENSG00000011478.10,QPCTLTHCAEAGT_cells_CD81.2181e-04-0.1760image
chr19:45703307-45703982:+THYMEERMacrophages_M19.9904e-040.3449image
ENSG00000011478.10,QPCTLTHYMEAGMacrophages_M19.9904e-040.3449image
chr19:45703307-45703982:+UCECEERDendritic_cells_activated9.8595e-050.2934image
ENSG00000011478.10,QPCTLUCECEAGDendritic_cells_activated9.8054e-050.2934image
chr19:45703307-45703982:+UCSEERT_cells_regulatory_(Tregs)1.8262e-020.3202image
ENSG00000011478.10,QPCTLUCSEAGT_cells_regulatory_(Tregs)1.8359e-020.3199image
chr19:45703307-45703982:+UVMEERDendritic_cells_resting5.2375e-030.3132image
ENSG00000011478.10,QPCTLUVMEAGDendritic_cells_resting5.2375e-030.3132image


Top

6. Enriched editing regions and immune gene sets for QPCTL


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:45703307-45703982:+KIRPEER3.2656e-02image5.1417e-03-0.1754image
ENSG00000011478.10,QPCTLKIRPEAG3.3341e-02image5.3286e-03-0.1747image
chr19:45703307-45703982:+LIHCEER2.5550e-02image1.9671e-030.1721image
ENSG00000011478.10,QPCTLLIHCEAG2.5524e-02image1.9667e-030.1721image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000011478.10,QPCTLBLCAEAG2.3407e-030.15712.0757e-020.11971.0053e-030.16964.5124e-050.2096image
chr19:45703307-45703982:+BLCAEER2.8079e-030.15451.9035e-020.12151.2179e-030.16717.9173e-050.2032image
ENSG00000011478.10,QPCTLLIHCEAG5.8696e-05-0.22232.3300e-03-0.16945.1853e-05-0.22392.2810e-030.1697image
chr19:45703307-45703982:+LIHCEER5.8604e-05-0.22232.3281e-03-0.16945.1790e-05-0.22392.2785e-030.1697image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:45703307-45703982:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.2299e-120.3491image
ENSG00000011478.10,QPCTLBLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.2266e-120.3529image
ENSG00000011478.10,QPCTLBRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.5787e-110.2078image
chr19:45703307-45703982:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.5277e-110.2099image
ENSG00000011478.10,QPCTLCESCGSVA_HALLMARK_HEME_METABOLISMEAG5.5834e-100.3773image
chr19:45703307-45703982:+CESCGSVA_HALLMARK_HEME_METABOLISMEER5.5058e-100.3774image
chr19:45703307-45703982:+CHOLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.0438e-020.4608image
ENSG00000011478.10,QPCTLCHOLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.0561e-020.4604image
chr19:45703307-45703982:+COADGSVA_HALLMARK_COMPLEMENTEER5.1895e-050.2603image
ENSG00000011478.10,QPCTLCOADGSVA_HALLMARK_COMPLEMENTEAG4.9134e-050.2600image
ENSG00000011478.10,QPCTLDLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.6343e-020.2890image
chr19:45703307-45703982:+DLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.3172e-020.2931image
chr19:45693882-45696559:+ESCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.2589e-020.3960image
ENSG00000011478.10,QPCTLESCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.0480e-02-0.2729image
ENSG00000011478.10,QPCTLGBMGSVA_HALLMARK_MYC_TARGETS_V2EAG3.8540e-04-0.2807image
chr19:45703307-45703982:+GBMGSVA_HALLMARK_MYC_TARGETS_V2EER3.0634e-04-0.2853image
ENSG00000011478.10,QPCTLHNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.3109e-120.3663image
chr19:45703307-45703982:+HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.3109e-120.3663image
chr19:45703307-45703982:+KICHGSVA_HALLMARK_UV_RESPONSE_DNEER3.5142e-020.3221image
ENSG00000011478.10,QPCTLKICHGSVA_HALLMARK_UV_RESPONSE_DNEAG3.5142e-020.3221image
ENSG00000011478.10,QPCTLKIRCGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.2844e-080.3018image
chr19:45703307-45703982:+KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.4985e-080.3109image
chr19:45703307-45703982:+KIRPGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER5.1417e-03-0.1754image
ENSG00000011478.10,QPCTLKIRPGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG5.3286e-03-0.1747image
ENSG00000011478.10,QPCTLLAMLGSVA_HALLMARK_DNA_REPAIREAG4.4422e-040.4782image
ENSG00000011478.10,QPCTLLGGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG8.0124e-030.1875image
chr19:45703307-45703982:+LGGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER8.0124e-030.1875image
ENSG00000011478.10,QPCTLLIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.8783e-110.3602image
chr19:45703307-45703982:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.8695e-110.3602image
chr19:45703307-45703982:+LUADGSVA_HALLMARK_ANDROGEN_RESPONSEEER5.0011e-060.2280image
ENSG00000011478.10,QPCTLLUADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.8379e-060.2306image
ENSG00000011478.10,QPCTLLUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG6.7583e-040.1618image
chr19:45703307-45703982:+LUSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER8.7262e-040.1585image
ENSG00000011478.10,QPCTLMESOGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG5.6391e-04-0.4356image
chr19:45703307-45703982:+MESOGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER5.6391e-04-0.4356image
chr19:45703307-45703982:+OVGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER2.1973e-030.1984image
ENSG00000011478.10,QPCTLOVGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.2675e-030.2060image
chr19:45693882-45696559:+OVGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.2609e-03-0.4182image
chr19:45703307-45703982:+PAADGSVA_HALLMARK_UV_RESPONSE_DNEER7.0273e-030.2185image
ENSG00000011478.10,QPCTLPAADGSVA_HALLMARK_UV_RESPONSE_DNEAG6.7140e-030.2197image
ENSG00000011478.10,QPCTLPCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.6182e-030.2124image
chr19:45703307-45703982:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.8670e-030.2116image
ENSG00000011478.10,QPCTLPRADGSVA_HALLMARK_APICAL_JUNCTIONEAG1.5052e-040.1699image
chr19:45703307-45703982:+PRADGSVA_HALLMARK_APICAL_JUNCTIONEER8.9885e-050.1756image
chr19:45703307-45703982:+READGSVA_HALLMARK_MYC_TARGETS_V2EER2.9407e-03-0.3264image
ENSG00000011478.10,QPCTLREADGSVA_HALLMARK_MYC_TARGETS_V2EAG2.6951e-03-0.3292image
ENSG00000011478.10,QPCTLSARCGSVA_HALLMARK_UV_RESPONSE_DNEAG4.1178e-030.2159image
chr19:45703307-45703982:+SARCGSVA_HALLMARK_UV_RESPONSE_DNEER4.1178e-030.2159image
chr19:45693882-45696559:+SKCMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.2268e-020.4381image
chr19:45703307-45703982:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.2424e-060.2075image
ENSG00000011478.10,QPCTLSKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.1592e-060.2076image
ENSG00000011478.10,QPCTLSTADGSVA_HALLMARK_P53_PATHWAYEAG1.1862e-020.2144image
chr19:45693882-45696559:+STADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.4726e-030.4048image
chr19:45703307-45703982:+STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.4963e-020.2112image
chr19:45703307-45703982:+TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER3.7667e-020.1771image
ENSG00000011478.10,QPCTLTGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.1259e-020.1740image
chr19:45703307-45703982:+THCAGSVA_HALLMARK_MITOTIC_SPINDLEEER7.3603e-110.2939image
ENSG00000011478.10,QPCTLTHCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.4993e-110.2938image
chr19:45703307-45703982:+THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.5394e-070.5074image
ENSG00000011478.10,QPCTLTHYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.5394e-070.5074image
chr19:45703307-45703982:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.4595e-070.3678image
ENSG00000011478.10,QPCTLUCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.4053e-070.3679image
ENSG00000011478.10,QPCTLUCSGSVA_HALLMARK_APOPTOSISEAG2.4391e-020.3061image
chr19:45703307-45703982:+UCSGSVA_HALLMARK_APOPTOSISEER2.4471e-020.3059image


Top

7. Enriched editing regions and drugs for QPCTL


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:45703307-45703982:+BLCAAICAREER8.9474e-08-0.2729image
ENSG00000011478.10,QPCTLBLCAAICAREAG1.9992e-07-0.2653image
chr19:45703307-45703982:+BRCAEHT.1864EER2.8571e-050.1343image
ENSG00000011478.10,QPCTLBRCAEHT.1864EAG4.4275e-050.1309image
ENSG00000011478.10,QPCTLCESCDMOGEAG1.0026e-04-0.2421image
chr19:45703307-45703982:+CESCDMOGEER1.0105e-04-0.2420image
chr19:45703307-45703982:+CHOLCCT007093EER9.5892e-03-0.5076image
ENSG00000011478.10,QPCTLCHOLCCT007093EAG9.4461e-03-0.5085image
chr19:45703307-45703982:+COADGW843682XEER1.3629e-030.2073image
ENSG00000011478.10,QPCTLCOADCCT007093EAG4.6439e-03-0.1829image
chr19:45703307-45703982:+DLBCCGP.082996EER1.5211e-020.3485image
ENSG00000011478.10,QPCTLDLBCCGP.082996EAG1.5503e-020.3476image
ENSG00000011478.10,QPCTLESCAEtoposideEAG1.1837e-02-0.3153image
ENSG00000011478.10,QPCTLGBMDMOGEAG3.4299e-06-0.3620image
chr19:45703307-45703982:+GBMDMOGEER3.0276e-06-0.3638image
ENSG00000011478.10,QPCTLHNSCBMS.708163EAG5.6533e-07-0.2658image
chr19:45703307-45703982:+HNSCBMS.708163EER5.6533e-07-0.2658image
chr19:45703307-45703982:+KICHCGP.60474EER5.6164e-030.4153image
ENSG00000011478.10,QPCTLKICHCGP.60474EAG5.6164e-030.4153image
chr19:45703307-45703982:+KIRCGNF.2EER3.3773e-080.3081image
ENSG00000011478.10,QPCTLKIRCGNF.2EAG1.0398e-070.2970image
ENSG00000011478.10,QPCTLKIRPCGP.60474EAG3.3640e-040.2237image
chr19:45703307-45703982:+KIRPCGP.60474EER3.3855e-040.2236image
ENSG00000011478.10,QPCTLLAMLImatinibEAG8.3481e-030.3691image
chr19:45703307-45703982:+LGGKIN001.135EER8.7788e-030.1853image
ENSG00000011478.10,QPCTLLGGKIN001.135EAG8.7788e-030.1853image
chr19:45703307-45703982:+LIHCBleomycinEER8.0382e-090.3183image
ENSG00000011478.10,QPCTLLIHCBleomycinEAG8.0694e-090.3182image
ENSG00000011478.10,QPCTLLUADDoxorubicinEAG1.8037e-03-0.1570image
chr19:45703307-45703982:+LUADDoxorubicinEER1.6660e-03-0.1581image
ENSG00000011478.10,QPCTLLUSCGefitinibEAG5.1957e-03-0.1335image
chr19:45703307-45703982:+LUSCGefitinibEER1.0147e-02-0.1229image
chr19:45703307-45703982:+MESOBAY.61.3606EER2.2462e-03-0.3902image
ENSG00000011478.10,QPCTLMESOBAY.61.3606EAG2.2462e-03-0.3902image
chr19:45693882-45696559:+OVAKT.inhibitor.VIIIEER2.6600e-030.4121image
chr19:45703307-45703982:+OVEmbelinEER8.9318e-04-0.2149image
ENSG00000011478.10,QPCTLOVEpothilone.BEAG3.8286e-03-0.1853image
ENSG00000011478.10,QPCTLPAADBIBW2992EAG5.2773e-030.2260image
chr19:45703307-45703982:+PAADBIBW2992EER5.5080e-030.2248image
chr19:45703307-45703982:+PCPGJNK.Inhibitor.VIIIEER6.9719e-03-0.2180image
ENSG00000011478.10,QPCTLPCPGJNK.Inhibitor.VIIIEAG7.2988e-03-0.2168image
ENSG00000011478.10,QPCTLPRADCCT007093EAG2.1324e-05-0.1902image
chr19:45703307-45703982:+PRADCCT007093EER5.2137e-05-0.1814image
chr19:45703307-45703982:+READGW843682XEER5.2593e-030.3073image
ENSG00000011478.10,QPCTLREADGW843682XEAG5.3229e-030.3069image
chr19:45703307-45703982:+SARCImatinibEER2.1533e-03-0.2305image
ENSG00000011478.10,QPCTLSARCImatinibEAG2.1533e-03-0.2305image
chr19:45693882-45696559:+SKCMEtoposideEER3.7938e-020.4260image
chr19:45703307-45703982:+SKCMDMOGEER1.3081e-05-0.2017image
ENSG00000011478.10,QPCTLSKCMDMOGEAG1.1143e-05-0.2033image
ENSG00000011478.10,QPCTLSTADAZ628EAG1.0643e-03-0.2767image
chr19:45693882-45696559:+STADBIRB.0796EER3.8238e-030.3710image
chr19:45703307-45703982:+STADAZD.2281EER4.7153e-03-0.2818image
ENSG00000011478.10,QPCTLTHCACEP.701EAG1.0117e-080.2601image
chr19:45703307-45703982:+THCACEP.701EER1.0191e-080.2600image
ENSG00000011478.10,QPCTLTHYMElesclomolEAG6.0308e-060.4615image
chr19:45703307-45703982:+THYMElesclomolEER6.0308e-060.4615image
chr19:45703307-45703982:+UCECJNK.Inhibitor.VIIIEER2.0640e-04-0.2801image
ENSG00000011478.10,QPCTLUCECJNK.Inhibitor.VIIIEAG2.0337e-04-0.2804image
ENSG00000011478.10,QPCTLUCSMetforminEAG2.7292e-03-0.4000image
chr19:45703307-45703982:+UCSMetforminEER2.7801e-03-0.3993image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType